Clinical

Dataset Information

0

Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy


ABSTRACT: This is an open-label, multicenter, randomized phase 2 study evaluating the efficacy and safety of fruquintinib plus capecitabine versus capecitabine as maintenance therapy for metastatic colorectal cancer after first-line treatment. Patients who have already achieved disease control (including CR/PR and SD) after ≥6 cycles of standard first-line induction treatment, and are still unresectable would be assigned into 2 maintenance treatment groups by randomization in a 1:1 ratio to receive fruquintinib + capecitabine or capecitabine. All patients will be treated until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal.

DISEASE(S): Colorectal Cancer Stage Iv,Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2740471 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2365787 | ecrin-mdr-crc
| 2387531 | ecrin-mdr-crc
| 2749552 | ecrin-mdr-crc
| 3051 | ecrin-mdr-crc
| 2332139 | ecrin-mdr-crc
| 2200070 | ecrin-mdr-crc
| 116737 | ecrin-mdr-crc
2014-11-14 | E-GEOD-63216 | biostudies-arrayexpress
| 2375937 | ecrin-mdr-crc
2022-08-21 | GSE211373 | GEO